Ethnic Differences in Mechanisms of Action of Dupilumab

Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with AD. This trial will determine differences in inflammatory responses to dupilumab between Caucasian, Asian, and African American patients with AD. The central hypothesis of this study is that ethnic differences in both immune and stromal cells contribute to variability in AD presentation and response to anti-interleukin-4 receptor (IL-4R) inhibition with dupilumab.

NCT Number	NCT05268107
Lead Sponsor	University of Michigan Collaborators: Regeneron Pharmaceuticals
Conditions	Atopic Dermatitis
Enrollment	30 participants
Start Date	2023-01-25
Primary Completion	2026-12 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2025-11-06